This month Vertex plans to present initial efficacy results for a drug it believes will avoid the toxicity problems of Boehringer's compound.

FORBES: Magazine Article

The uncertainty sent Vertex stock gyrating because the initial data suggested prescriptions had stopped growing.

FORBES: The Hepatitis C Wars: What Docs Say About The Newest Meds

Initial results were very promising, but then Vertex had to restate them.

FORBES: The Most Important New Drug Of 2012